Key regions: United States, Europe, Brazil, Japan, United Kingdom
Bronchodilator Drugs market in EU-27 has been experiencing significant growth in recent years.
Customer preferences: Bronchodilator drugs are primarily used to treat respiratory diseases such as asthma, chronic obstructive pulmonary disease (COPD), and bronchitis. The increasing prevalence of respiratory diseases among the population has resulted in a surge in demand for bronchodilator drugs. Additionally, the rising geriatric population, who are more prone to respiratory diseases, has also contributed to the growth of the market.
Trends in the market: The market for bronchodilator drugs in EU-27 is witnessing a shift towards combination therapies that offer better efficacy and convenience to patients. Combination therapies, which include a combination of bronchodilators and inhaled corticosteroids, have been gaining popularity due to their ability to provide quick relief and long-term control of respiratory symptoms.Furthermore, the market is also witnessing an increasing trend towards the adoption of digital health technologies. Digital health technologies, such as inhaler sensors and mobile apps, are being used to monitor patient adherence to medication and to provide personalized treatment plans. This trend is expected to continue in the future, as it offers several benefits such as improved patient outcomes and reduced healthcare costs.
Local special circumstances: Germany is the largest market for bronchodilator drugs in EU-27, owing to its large population and high prevalence of respiratory diseases. The market in Germany is characterized by the presence of several multinational pharmaceutical companies, which offer a wide range of bronchodilator drugs. Additionally, the market in Germany is highly regulated, which has resulted in the availability of high-quality and safe bronchodilator drugs.France is another significant market for bronchodilator drugs in EU-27. The market in France is characterized by a high degree of innovation, with several pharmaceutical companies investing in research and development of new drugs. Additionally, the market in France is highly competitive, with several domestic and international players competing for market share.
Underlying macroeconomic factors: The growth of the bronchodilator drugs market in EU-27 can be attributed to several macroeconomic factors. The increasing prevalence of respiratory diseases, rising geriatric population, and the adoption of combination therapies and digital health technologies are some of the key factors driving the growth of the market.Additionally, the increasing healthcare expenditure and the availability of advanced healthcare infrastructure in EU-27 countries have also contributed to the growth of the market. However, the market is also facing several challenges such as the high cost of bronchodilator drugs, the availability of alternative treatments, and the side effects associated with long-term use of bronchodilator drugs.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
